Drug metabolism, also known as biotransformation, is the chemical alteration of xenobiotics within the living body. The primary goal of this biological process is to convert active, lipid-soluble drug molecules into polar, water-soluble compounds that can be easily excreted by the kidneys or biliary system. Without metabolism, many lipophilic drugs would persist in the body indefinitely by continuously reabsorbing across renal tubular membranes. Biotransformation generally changes active drugs into inactive metabolites, though some drugs enter the body as inactive prodrugs that metabolism converts into therapeutic agents.
While almost every tissue possesses some metabolic capacity, the liver is the undisputed powerhouse of drug biotransformation due to its massive blood supply and high concentration of drug-metabolizing enzymes.
Phase I reactions modify chemical structures by introducing or unmasking a polar functional group, such as -OH, -NH2, or -SH. This slight change usually results in the loss of pharmacological activity or prepares the molecule for the next stage of processing.
The Cytochrome P450 (CYP450) superfamily represents the most important oxidative enzyme pathway in human pharmacology. Anchored in the membrane of the smooth endoplasmic reticulum in hepatocytes, these hemoproteins require molecular oxygen and NADPH to function. CYP3A4, CYP2D6, and CYP2C9 are responsible for metabolizing the vast majority of clinically prescribed drugs. Genetic polymorphisms within these genes explain why patients respond differently to identical doses of standard medications.
If a metabolite resulting from Phase I is still not sufficiently water-soluble for excretion, it undergoes Phase II. These synthetic reactions attach a large, endogenous polar molecule to the drug structure, creating a highly polar conjugate that is virtually inactive and ready for renal or biliary elimination.
Metabolic enzymes are dynamic systems susceptible to external chemical influences. Enzyme induction occurs when a substance increases the synthesis of CYP450 enzymes, accelerating the breakdown of co-administered drugs and potentially causing therapeutic failure. Conversely, enzyme inhibition happens when a drug blocks metabolic activity, causing substrate accumulation, elevated plasma concentrations, and severe toxicity. Recognizing these interactions prevents adverse clinical outcomes in multi-drug regimens.
Orally administered drugs must pass through the intestinal wall and travel via the portal vein directly to the liver before reaching the systemic circulation. During this journey, a significant fraction of the drug can be metabolized and inactivated. This phenomenon is known as the first-pass effect. Because of this hepatic and gut clearance, oral bioavailability—the fraction of unchanged drug that reaches systemic circulation—is often much lower than that of intravenous administration, requiring higher oral doses to achieve therapeutic equivalence.
Pharmacokinetics vary across populations due to a blend of genetic, environmental, and nutritional elements. Genetic polymorphisms in CYP450 genes, such as CYP2A6 or CYP2B6 variants common in African populations, alter how patients process specific antimalarials, anti-retrovirals, and antihypertensives. Additionally, local dietary habits, chronic herbal supplement co-administration, endemic infections, and liver pathology heavily influence enzymatic clearance rates, making individualized dosing essential for safe nursing practice.